GlassScriptPhysician profile
Danika Scott
NPI 1285211276
$2,167.00
in general payments reported to CMS, 2019-2025
26 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $575 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.01 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $319.82 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $304.61 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $220.00 | 2025 | |
| Janssen Biotech, INC. | $157.92 | 2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $156.80 | 2024-2025 | Jakafi |
| Alexion Pharmaceuticals, INC. | $132.25 | 2024 | Ultomiris |
| Caris Mpi, INC. | $131.00 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $94.95 | 2025 | Besremi |
| Pfizer INC. | $62.88 | 2025 | |
| Emd Serono, INC. | $60.44 | 2024 | |
| Array Biopharma INC | $58.40 | 2024-2025 | Lorbrena, Braftovi, Xalkori |
| Genzyme Corporation | $55.91 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.90 | 2025 | Ninlaro, Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $45.17 | 2025 | |
| Exelixis INC. | $36.03 | 2025 | Cabometyx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $32.55 | 2024 | |
| Tempus Ai, INC | $29.33 | 2025 | Xt Cdx |
| Daiichi Sankyo INC. | $29.04 | 2025 | Enhertu |
| Glaxosmithkline, LLC. | $28.85 | 2025 | Blenrep |
| Tersera Therapeutics LLC | $26.59 | 2025 | Zoladex |
| Agios Pharmaceuticals, INC. | $24.04 | 2024 | Pyrukynd |
| Csl Behring | $23.96 | 2025 | Idelvion, Afstyla |
| Bayer Healthcare Pharmaceuticals INC. | $23.37 | 2025 | |
| Eisai INC. | $23.35 | 2025 | |
| Sumitomo Pharma America, INC. | $19.92 | 2025 | Orgovyx |
| Lilly USA, LLC | $18.92 | 2024 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danika Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.